MX2021007178A - Derivados de quinolina para usarse en el tratamiento o prevencion del cancer. - Google Patents

Derivados de quinolina para usarse en el tratamiento o prevencion del cancer.

Info

Publication number
MX2021007178A
MX2021007178A MX2021007178A MX2021007178A MX2021007178A MX 2021007178 A MX2021007178 A MX 2021007178A MX 2021007178 A MX2021007178 A MX 2021007178A MX 2021007178 A MX2021007178 A MX 2021007178A MX 2021007178 A MX2021007178 A MX 2021007178A
Authority
MX
Mexico
Prior art keywords
sub
cancer
prevention
treatment
quinoline derivatives
Prior art date
Application number
MX2021007178A
Other languages
English (en)
Spanish (es)
Inventor
Hartmut Ehrlich
Didier Scherrer
Jamal Tazi
Philippe Pouletty
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of MX2021007178A publication Critical patent/MX2021007178A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
MX2021007178A 2018-12-20 2019-12-19 Derivados de quinolina para usarse en el tratamiento o prevencion del cancer. MX2021007178A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306783.4A EP3669874A1 (en) 2018-12-20 2018-12-20 Quinoline derivatives for use in the treatment or prevention of cancer
PCT/EP2019/086470 WO2020127839A1 (en) 2018-12-20 2019-12-19 Quinoline derivatives for use in the treatment or prevention of cancer

Publications (1)

Publication Number Publication Date
MX2021007178A true MX2021007178A (es) 2021-07-07

Family

ID=65200518

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007178A MX2021007178A (es) 2018-12-20 2019-12-19 Derivados de quinolina para usarse en el tratamiento o prevencion del cancer.

Country Status (11)

Country Link
US (1) US20220071985A1 (https=)
EP (2) EP3669874A1 (https=)
JP (1) JP7570641B2 (https=)
KR (2) KR20210136969A (https=)
CN (2) CN113543784A (https=)
AU (1) AU2019408244B2 (https=)
BR (1) BR112021012132A2 (https=)
IL (1) IL284124B2 (https=)
MA (1) MA54512A (https=)
MX (1) MX2021007178A (https=)
WO (1) WO2020127839A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
CN120152971A (zh) * 2022-11-25 2025-06-13 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物晶型及其制备方法
WO2025027388A1 (en) 2023-08-01 2025-02-06 Abivax Obefazimod for treatment of ulcerative colitis
CN121532389A (zh) * 2023-08-30 2026-02-13 江苏正大丰海制药有限公司 用于调节微小rna-124活性的化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
EP2757161A1 (en) * 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
CN103787992B (zh) * 2014-01-21 2016-04-20 华东理工大学 N,n-双取代苯并氮杂环-2-胺类化合物及其用途
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
JP6474334B2 (ja) 2015-07-30 2019-02-27 株式会社キーエンス 画像検査装置、画像検査方法および画像検査プログラム
PT3429998T (pt) * 2016-03-18 2021-11-04 Prosynergia S A R L Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais

Also Published As

Publication number Publication date
US20220071985A1 (en) 2022-03-10
EP3669874A1 (en) 2020-06-24
JP2022513517A (ja) 2022-02-08
IL284124A (en) 2021-08-31
IL284124B1 (en) 2025-03-01
CN118986981A (zh) 2024-11-22
KR20210136969A (ko) 2021-11-17
CN113543784A (zh) 2021-10-22
MA54512A (fr) 2021-10-27
JP7570641B2 (ja) 2024-10-22
WO2020127839A1 (en) 2020-06-25
AU2019408244A1 (en) 2021-07-08
CA3122912A1 (en) 2020-06-25
KR20250117703A (ko) 2025-08-05
AU2019408244B2 (en) 2025-03-20
IL284124B2 (en) 2025-07-01
BR112021012132A2 (pt) 2021-09-08
EP3897639A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
MX2021007178A (es) Derivados de quinolina para usarse en el tratamiento o prevencion del cancer.
MX2024015470A (es) Derivados de quinolina para usarse en el tratamiento de enfermedades inflamatorias
JP2022544714A5 (https=)
JP2020532578A5 (https=)
WO2010143169A3 (en) Compounds useful for treating aids
CN114222740A (zh) 新型极光激酶抑制剂及其用途
RU2017146408A (ru) Тетразамещенные алкеновые соединения и их применение
JP2015516420A5 (https=)
IN2012DN00573A (https=)
MX2009013254A (es) Derivados 3-amino-6(1-amino-etil)-tetrahidropirano.
JP2007506740A5 (https=)
JP2016514138A5 (https=)
DK148844C (da) Analogifremgangsmaade til fremstilling af dihydroxyalkylsubstituerede xanthinderivater
JP2016514139A5 (https=)
IL274291B1 (en) Compounds and their use in proliferation of stem cells and/or progenitor cells
MX2012008147A (es) Derivados de pirrazolopiridina.
WO1999051588A1 (en) Quinolonecarboxylic acid derivatives or salts thereof
JP2009506075A5 (https=)
JP2019526593A5 (https=)
GB1098805A (en) Novel benzothiazinones
WO2000034273A3 (de) 3-(heterocyclyl)-substituierte benzoylpyrazole
NZ545995A (en) Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
JP2023524813A5 (https=)
NO20062936L (no) Fremgangsmate for fremstilling av N-alkyl-2(hydroksy-4-benzoyl)-3-benzofuraner og dets mellomprodukter derav
JP2021534084A5 (https=)